S-268024 + Nuvaxovid

S-268024 + Nuvaxovid refers to a combination or comparative clinical regimen involving two recombinant protein-based COVID-19 vaccines. S-268024 is a bivalent vaccine candidate developed by Shionogi & Co., Ltd., which incorporates spike protein antigens from both the ancestral SARS-CoV-2 strain and the Omicron BA.1 variant, utilizing a proprietary oil-in-water adjuvant (A-910823). Nuvaxovid (NVX-CoV2373), developed by Novavax and manufactured/distributed by Shionogi in Japan, is a monovalent protein subunit vaccine containing the ancestral spike protein and the saponin-based Matrix-M adjuvant. This combination is primarily associated with Phase 3 clinical trials evaluating the immunogenicity and safety of S-268024 as a booster dose, often compared against or following primary series vaccination with Nuvaxovid. The regimen aims to provide enhanced protection against emerging SARS-CoV-2 variants by leveraging the strengths of recombinant protein technology and diverse antigenic targets.

Other names

S-268024S268024S 268024NVX-CoV2373NVX-CoV-2373NVX-CoV 2373Covovax